DMRA — Damora Therapeutics, Inc. stock price, charts and financials

Latest market price

30.02

+1.46+5.11%

Overview Short InterestFilings

DMRAQT92Damora Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

30.02+5.11%

Earnings

Up 5.1% — Reported earnings — EPS missed by 60%.

High confidence

Loading chart...

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	3.15%	Shs Outstand	61.55M	Perf Week	2.04%

Market Cap	1.85B	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-0.01%	Shs Float	41.22M	Perf Month	0.74%

Enterprise Value	1.32B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	11.37%	Perf Quarter	15.77%

Income	-210.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	8.56	Perf Half Y	9.72%

Sales	0.00	P/B	3.62	EPS next Y	-6.92%	ROA	-43.91%	Short Interest	4.69M	Perf YTD	30.47%

Book/sh	8.29	P/C	3.47	EPS next 5Y	-	ROE	-122.61%	52W High	38.33 -21.68%	Perf Year	838.13%

Cash/sh	8.66	P/FCF	-	EPS past 3/5Y	-	ROIC	-46.73%	52W Low	2.45 1125.31%	Perf 3Y	-60.24%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.81% 8.09%	Perf 5Y	-71.68%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	52.39%	Oper. Margin	0.00%	ATR (14)	2.27	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	22.48	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	55.57	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	22.48	EPS Q/Q	67.71%	SMA20	0.67%	Beta	1.45	Target Price	43.75

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	14.82%	Rel Volume	0.93	Prev Close	28.56

Employees	7	LT Debt/Eq	0.07	Earnings	Aug 04	SMA200	25.39%	Avg Volume	589.49K	Price	30.02

IPO Date	Oct 29, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-59.89% -	Net Debt/EBITDA	2.26	Volume	551,108	Change	5.11%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	Wedbush	Outperform	$35 → $40
Jul-26-26	Initiated	Jefferies	Buy	$50
Jun-11-26	Initiated	H.C	Buy	$45
May-28-26	Initiated	Wedbush	Outperform	$35
Apr-23-26	Initiated	RBC Capital	Outperform	$40

Latest News

Aug-03-26

Aug-03-2604:01PM

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-30-26

Jul-30-2609:42AM

Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40Benzinga

Jul-27-26

Jul-27-2608:01AM

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For MondayBenzinga

Jul-21-26

Jul-21-2608:01AM

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga

Jul-17-26

Jul-17-2608:00AM

Damora Announces Redomestication from Delaware to Cayman Islandsglobenewswire.com

Jul-01-26

Jul-01-2604:01PM

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jun-12-26

Jun-12-2610:07AM

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price TargetBenzinga

Jun-11-26

Jun-11-2607:55AM

HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45Benzinga

Company

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	1	0	0	0	0	0
Gross Profit	0	0	-1	0	0	0	0	0
Selling, General and Administrative Excl. Other	10	10	12	13	13	9	2	3
Research and Development	201	6	24	48	38	25	37	10
Other Operating Expense	0	1	0	0	1	-1	0	0
Operating Income	-211	-17	-36	-61	-52	-34	-39	-13
Interest Expense	0	0	0	0	0	0	0	3
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	1	-5	-2	0	0	-1	2	0
Net Income Before Taxes	-210	-21	-38	-62	-52	-35	-37	-16
Income Taxes	0	0	0	0	0	0	0	0
Consolidated Net Income	-210	-21	-38	-62	-52	-35	-37	-16
Net Income From Continuing Operations	-210	-21	-38	-62	-52	-35	-37	-16
Net Income	-210	-21	-38	-62	-52	-35	-37	-16
EPS (Recurring)	-152.99	-18.53	-36.08	-60.63	-51.22	-34.48	-41.35	-18.68
EPS (Basic, Before Extraordinaries)	-152.99	-18.53	-36.08	-60.63	-51.22	-34.48	-41.35	-18.68
EPS (Diluted)	-152.99	-18.53	-36.08	-60.63	-51.22	-34.48	-41.35	-18.68
EBITDA	-210	-21	-38	-61	-51	-33	-39	-13
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	1	1	1	1	1	1	1	1
Market Capitalization	23	5	18	29	76	313	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Winslow Garrett	General Counsel	Jul 06 '26	Sale	29.98	245	7,345	2,289	Jul 07
Winslow Garrett	General Counsel	Jul 03 '26	Option Exercise	0.00	680	0	2,534	Jul 07

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.